Microbiome–Drug Interactions: Emerging Insights into Therapeutic Response and Personalized Pharmacological Strategies

Abstract

The human microbiome has emerged as a critical biological factor influencing drug response,
therapeutic effectiveness, and individual variability in pharmacological outcomes.
Traditionally, drug metabolism and therapeutic response have been primarily associated with
host genetic factors and physiological characteristics; however, increasing evidence indicates
that microbial communities residing within the human body, particularly the intestinal
microbiota, play an essential role in modifying drug activity through complex biochemical
interactions. Microorganisms can directly metabolize pharmaceutical compounds, alter drug
bioavailability, influence pharmacokinetic profiles, and regulate host metabolic pathways
associated with therapeutic response.
Microbiome–drug interactions represent a rapidly expanding area of biomedical research with
significant implications for personalized medicine. Variations in microbial composition
among individuals may contribute to differences in treatment efficacy, drug toxicity, and
adverse reactions, creating new opportunities for microbiome-guided therapeutic strategies.
Understanding these interactions may support the development of predictive approaches that
integrate microbial characteristics with conventional pharmacological parameters for
optimized treatment selection.
This review discusses the fundamental mechanisms involved in microbiome-mediated drug
interactions, including microbial enzymatic transformation, metabolic regulation, and
host–microbe communication pathways. It further examines the influence of gut microbiota
on pharmacokinetics and pharmacodynamics, with emphasis on personalized
pharmacological approaches. The article also highlights current clinical applications,
challenges associated with microbiome-based therapeutic development, and future
opportunities for integrating microbiome analysis into precision healthcare.
Although microbiome-based pharmacology is still developing, advances in sequencing
technologies, computational biology, and systems-level analysis are improving the understanding of microbial contributions to drug response. The integration of microbiome
science with pharmacological research may provide innovative strategies for improving
therapeutic outcomes and developing individualized treatment approaches.